Find Patient Assistance

Answer a few simple questions to find out which patient assistance option might be right for your patient.

  • Is your patient insured?

  • Does the patient's insurance cover his or her Tarceva?

  • Does your patient have commercial insurance?

    What does this mean?
  • Has your patient already been referred to the Genentech BioOncology Co-pay Card and is either ineligible or no longer receiving assistance?

  • Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?

  • Is the patient 18 years of age or older?

Your Patient Might Qualify for a Referral to the Genentech BioOncology Co-pay Card

If eligible commercially insured patients need assistance with their out-of-pocket costs, Tarceva Access Solutions can refer them to the Genentech BioOncology Co-pay Card.*

 

Learn More

 

*In order to be eligible for the Genentech BioOncology Co-pay Card, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit CopayAssistanceNow.com for the full list of terms and conditions.

Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation

For eligible patients with commercial or public health insurance, Tarceva Access Solutions offers referrals to independent co-pay assistance foundations.*

 

Learn More

 

*Genentech and Astellas Pharma US do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Tarceva Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s or Astellas Pharma US's endorsement or financial support. There may be other foundations to support the patient's disease state.

Your Patient Might Qualify for a Referral to the Genentech Patient Foundation

The Genentech Patient Foundation provides free Tarceva to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.*

 

Learn More

 

*To be eligible for free Tarceva from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Genentech BioOncology Co-pay Card and support from independent co-pay assistance foundations) and must meet financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.

Patient Assistance Options

Referrals to the Genentech BioOncology Co-pay Card

Tarceva Access Solutions can refer eligible patients to the Genentech BioOncology Co-pay Card for help with the out-of-pocket costs associated with Tarceva.*

Learn More

Referrals to Independent Co-pay Assistance Foundations

For eligible patients with commercial or public health insurance, Tarceva Access Solutions offers referrals to independent co-pay assistance foundations.†

Learn More

Referrals to the Genentech Patient Foundation

The Genentech Patient Foundation provides free Tarceva to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.‡

Learn More

*In order to be eligible for the Genentech BioOncology Co-pay Card, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit CopayAssistanceNow.com for the full list of terms and conditions.

†Genentech and Astellas Pharma US do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Tarceva Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s or Astellas Pharma US's endorsement or financial support. There may be other foundations to support the patient's disease state.

‡To be eligible for free Tarceva from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Genentech BioOncology Co-pay Card and support from independent co-pay assistance foundations) and must meet financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.

Important Safety Information & Indication

Indications

Metastatic Non-Small Cell Lung Cancer (NSCLC)

Tarceva is indicated for:

  • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.

Limitations of use:

  • Safety and efficacy of Tarceva have not been established in patients with NSCLC whose tumors have other EGFR mutations.
  • Tarceva is not recommended for use in combination with platinum-based chemotherapy.

Pancreatic Cancer

Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.

Important Safety Information

  • WARNINGS AND PRECAUTIONS:
    • Cases of serious interstitial lung disease (ILD), including fatal cases, have been reported.
    • Hepatic failure, hepatorenal syndrome, and severe acute renal failure (all including fatal cases) and renal insufficiency have been reported.
    • Gastrointestinal perforation (including fatal cases) has been reported.
    • Bullous, blistering and exfoliative skin conditions, including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, which in some cases were fatal, have been reported.
    • In the pooled incidences in the 3 monotherapy lung studies and the pancreatic carcinoma trial, serious adverse reactions, including fatal cases, such as cerebrovascular accident and microangiopathic hemolytic anemia with thrombocytopenia were reported.
    • Decreased tear production, abnormal eyelash growth, keratoconjunctivitis sicca or keratitis can occur and can lead to corneal perforation or ulceration.
    • Severe and fatal hemorrhage associated with International Normalized Ratio (INR) elevations can occur when Tarceva and warfarin are used concurrently.
    • Embryo-fetal toxicity. Women should be advised to avoid pregnancy or breastfeeding.
  • MOST COMMON ADVERSE REACTIONS:
    • Metastatic NSCLC – First-Line Treatment of Patients With EGFR Mutations:
      • Diarrhea, asthenia, rash, cough, dyspnea, and decreased appetite.
    • Metastatic NSCLC – Maintenance Treatment:
      • Rash and diarrhea.
    • Metastatic NSCLC – Second/Third-line Treatment:
      • Rash and diarrhea.
    • Advanced Pancreatic Cancer – Tarceva Administered Concurrently with Gemcitabine:
      • Fatigue, rash, nausea, anorexia, and diarrhea.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional Important Safety Information, please see full Prescribing Information.